NUVATION BIO INC (NUVB:NYSE)
$5.8 -0.14 (-2.3569%)
Analysed NUVATION BIO INC (NUVB:NYSE) News Sources
Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?
04-08-2026
yahoo.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
06-08-2026
yahoo.com
Nuvation Bio Q2 Earnings Call Highlights
08-08-2026
marketbeat.com
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
18-08-2026
yahoo.com
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
20-08-2026
yahoo.com
JPMorgan sees 100% upside in overlooked cancer drug stock
20-08-2026
thestreet.com
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
31-08-2026
yahoo.com
Nuvation Bio to Participate in Upcoming Investor Conferences
02-09-2026
yahoo.com
Jim Cramer sends strong 5-word message on surging biotech stock
06-09-2026
thestreet.com
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
15-09-2026
yahoo.com
What is the current price of NUVATION BIO INC (NUVB:NYSE)?
The current price of NUVATION BIO INC (NUVB:NYSE) is $5.8.
NUVATION BIO INC (NUVB:NYSE) absolute price change since previous trading day?
The absolute price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is $-0.14.
NUVATION BIO INC (NUVB:NYSE) percentage price change since previous trading day?
The percentage price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is -2.3569%.
What is the most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE)?
The most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE) is 69 out of 100.
What is the most recent average sentiment for NUVATION BIO INC (NUVB:NYSE)?
The most recent sentiment for NUVATION BIO INC (NUVB:NYSE) is .
SEC-8K** Filing Available For NUVATION BIO INC (NUVB:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.